Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natural Dendritic Cells in mCRPC
NCT02692976Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2015
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Radboud University Medical Center. Primary endpoint: Immunogenicity of tumor-peptide loaded natural blood dendritic cells at 18 months. Started Sep 2015; status: completed.
02
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02692976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02692976.